Daxdilimab Improved Discoid Lupus Skin Activity by Week 4
Daxdilimab improved discoid lupus skin activity by week 4, HCPLive reports — an early efficacy signal for interferon-pathway blockade in cutaneous lupus. Full trial details are still pending.
Topic
Discoid Lupus Erythematosus
Topic
Discoid Lupus Erythematosus
Daxdilimab Improves Disease Activity in Refractory Discoid Lupus
A Phase 2 trial found daxdilimab improved disease activity in patients with treatment-refractory discoid lupus erythematosus, a h…